Bioprocessing platforms are evolving toward modular, flexible, and automated systems to efficiently produce diverse gene-edited therapies at scale. Ori Biotech exemplifies this shift with integrated core systems capable of rapid operator training and incorporation of best-in-class technologies. ProBio’s new large-scale GMP facility enhances plasmid and viral vector manufacturing capacity for cell and gene therapies, underscoring the growing infrastructure support for advanced therapeutics.